Patent intelligence · US
US 12138243
Antiviral use of FABP4 modulating compounds
Antiviral use of FABP4 modulating compounds
Patent details — US 12138243
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 12, 2024
- Expiration
- Nov 7, 2044
- Applicant
- CRESCENTA BIOSCIENCES
- Claims
- 50
- CPC classes
- A61K, A61K31/404, A61K45/06, A61P
Quick answer
US 12138243 (Antiviral use of FABP4 modulating compounds) is held by CRESCENTA BIOSCIENCES. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRESCENTA BIOSCIENCES
- Grant date
- Expiration
- Claims
- 50
- CPC classes
- A61K, A61K31/404, A61K45/06, A61P, A61P31/12
More from CRESCENTA BIOSCIENCES
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12138243?
US 12138243 (Antiviral use of FABP4 modulating compounds) is held by CRESCENTA BIOSCIENCES. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12138243?
CRESCENTA BIOSCIENCES is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12138243 expire?
Our index shows an expiration date of Nov 7, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.